Fig. 1

Summary of the matched cohorts of spironolactone users and non-users. ^aAlthough the total study period was from January 2006 to December 2015, the inclusion window is smaller owing to the minimum data requirements pre- and post-inclusion date. CKD, chronic kidney disease; MRA, mineralocorticoid receptor antagonist; PMTX+, PharMetrics Plus; T2D, type 2 diabetes